Research
Cost Comparison of Different Brands of Anti-Diabetic Drugs With Drug Prices Control Order Price List
Author(s): MN Solanki, BR Ahir* and CK Desai
Introduction: India, the “diabetes capital” of the world, 74 million diabetics with a prevalence of ~8.7% among the
adult population. People require lifelong treatment for diabetes. Six of the top 10 drugs sold in India are anti-diabetes
brands. For most multinational drug makers the diabetes market has been highly lucrative. Objective: This study was
undertaken to compare the price of anti-diabetic branded drugs with the Drug Price Control Order (DPCO) price list. Methods: This is a cross-sectional, observational study. The price of different branded anti-diabetic drugs (included
in NLEM) was obtained from drug compendia and different pharmacy stores situated in five zones of Ahmedabad.
A comparison was done between the price of branded drugs in compendia, Pharmacy store, and DPCO ceiling
price to find o.. Read More»
DOI:
0
Select your language of interest to view the total content in your interested language